Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Biotechnology

Healthcare
$39.15 +8.79%

+$2.32 today

Market cap
$1.83B
Beta
0.00
52W Low $23.00High $36.61

Volume 0.30M

Average 0.34M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$61.48M

FY 2025 · Annual

Investing Cash Flow

-$81.48M

FY 2025 · Annual

Financing Cash Flow

$156.30M

FY 2025 · Annual

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$63.9M
+ D&A$304.0K
+ Stock-Based Comp$2.0M
+ Deferred Tax$0
+ Working Capital$1.4M
- Other Non-Cash-$1.2M
= Operating Cash Flow-$61.5M
- Capex-$16.0K
= Free Cash Flow-$61.5M

Analysis

FY2025 free cash flow is -$61.5M. FCF conversion is 96.2% of net income. Operating cash flow was -$61.5M, with capex of -$16.0K. The largest bridge item is Stock-Based Comp at $2.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
4Statement of changes in beneficial ownershipSep 25, 2026
3Initial statement of beneficial ownershipSep 25, 2026

Does COAG generate free cash flow?

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) generated -$61.49M of free cash flow in fiscal 2025.

How much operating cash flow does COAG produce?

Operating cash flow was -$61.48M, before capital expenditures of $16,000.00.